Blood group A was associated with a 2.5-fold higher odds of major adverse cardiac events than blood group O with Covid-19.
It is suggested a 2-fold higher odds of major thrombotic events in blood group A vs. O in Covid-19.
No association between blood group type and all-cause mortality was found.
The 30-day MACE, major arterial and venous thrombotic events and all-cause mortality was highest for blood groups A and AB and lowest for blood groups O and B.
Blood group A was associated with a 2.5-fold higher odds of MACE than blood group O.
Blood group A is associated with an increased odds of MACE, whereas blood group O was associated with a reduction in the odds of MACE in patients with COVID-19.
Group A to be associated with increased risk of respiratory failure while blood group O was protective.
Natural anti-glycan ABO antibodies have been shown to inhibit SARS-CoV1 spike protein-angiotensin converting enzyme 2 mediated cellular entry.
Furthermore, non-O blood groups have been shown to be associated with increased arterial and venous thrombotic events possibly mediated by increased levels of von Willebrand factor and factor VIII in non-O blood groups.